Legal Immunity for Pharmaceutical Industry

The US Secretary of Health and Human Services, Kathleen Sebelius, has just signed a decree granting vaccine makers total legal immunity from any lawsuits that result from any new “Swine Flu” vaccine. Moreover, the $7 billion US Government fast-track program to rush vaccines onto the market is being done without even normal safety testing.
The mass vaccinations are to be carried out predominantly for pregnant women and children. So far, neither the WHO nor the CDC or any other scientific body has demonstrated required scientific proof for the existence of the alleged H1N1 Influenza A new virus. The decree by the Department of Health and Human Services grants immunity to those making a “swine flu” vaccine, under the provisions of a 2006 law for public health emergencies. Background: The last time the US Government faced a new “swine flu” virus was in 1976. There was a national vaccination campaign in which thousands later filed claims contending they suffered side effects from the shots. Federal officials vaccinated 40 million Americans during a national campaign. A pandemic never materialized, but thousands who got the shots filed injury claims, as they contracted a paralyzing condition called Guillain-Barre Syndrome or other side effects. At least 25 people died after receiving the vaccine and 500 developed Guillain-Barre syndrome, an inflammation of the nervous system which can cause paralysis and be fatal.
In the end, the 1976 Swine Flu vaccine proved far worse than the disease. This time, the government has taken steps to prevent any possible legal remedy should thousands of US citizens suffer severe complications as a result of being given untested vaccines.
The WHO in Geneva, on recommendation of the WHO’s Strategic Advisory Group on Immunizations (SAGE), declared the “Swine Flu” Pandemic, so that automatic emergency health response programs could be activated all over the world. But who is WHO’s SAGE group?
Its Chairman since 2005 has been the UK Director of Immunization at the British Department of Health, Dr David Salisbury. In the 1980’s Salisbury reportedly drew major fire for backing a massive vaccination of children with a multiple MMR vaccine manufactured by the predecessor company of GlaxoSmithKline. That vaccine was pulled off the market in Japan after significant numbers of children developed adverse reactions to the vaccine and the Japanese government was forced to pay significant compensation to the victims. In Sweden, the vaccine was removed from the market. Apparently, that had little impact on WHO-SAGE chairman Salisbury. In Canada, all MMR vaccines containing the Urabe strain of viruses were also withdrawn. This was before these vaccines were licensed by the Department of Health for use in the UK. According to one independent UK investigator, Alan Golding, “Smith-Kline-French, the pharmaceutical company who became Smith-Kline-Beecham and were involved in UK manufacture at that time, were concerned about these safety issues and were reluctant to obtain a UK license for their Urabe-containing vaccines. As a result of their ‘concern’, that children could be severely harmed by one of their products, they requested that the UK government indemnify them against possible legal action that might be taken as a result of ‘losses’ associated with the vaccine, which by then was known to carry significant risk to health. The UK government, advised by Professor Salisbury agreed to this request.”
Today the same Dr Salisbury is advocating global proliferation of untested H1N1 vaccines, also manufactured by the same firm, now called GlaxoSmithKline. The situation today is even worse. Now that the Obama Administration has signed a document of immunity from legal prosecution, the FDA in the United States and UK health authorities have decided to let Big Pharma put vaccine products onto the market before any tests of the possible harmful side effects of the vaccines are even known.
Curiously enough, a full year before any reported case of the current alleged H1N1, the major pharmaceutical company, Baxter, filed for a patent for H1N1 vaccine (Baxter Vaccine Patent Application US 2009/0060950 A1). The application states, “Suitable adjuvants can be selected from mineral gels, aluminium hydroxide, surface active substances, lysolecithin, pluronic polyols, polyanions or oil emulsions such as water in oil or oil in water, or a combination thereof. Of course the selection of the adjuvant depends on the intended use. E.g. toxicity may depend on the destined subject organism and can vary from no toxicity to high toxicity.” This means that there is no legal liability.•

Source: interinfo, 368, August 2009
Translation Current Concerns